Pregled bibliografske jedinice broj: 734866
Impact of aspirin resistance on outcomes among patients following coronary artery bypass grafting : exploratory analysis from randomized controlled trial (NCT01159639).
Impact of aspirin resistance on outcomes among patients following coronary artery bypass grafting : exploratory analysis from randomized controlled trial (NCT01159639). // Journal of thrombosis and thrombolysis, 39 (2014), 4; 522-531 doi:10.1007/s11239-014-1127-9 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 734866 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Impact of aspirin resistance on outcomes among patients following coronary artery bypass grafting : exploratory analysis from randomized controlled trial (NCT01159639).
Autori
Petričević, Mate ; Kopjar, Tomislav ; Gašparović, Hrvoje ; Miličić, Davor ; Svetina, Lucija, Zdilar, Boris ; Boban, Marko ; Mihaljević Zrno, Martina ; Biočina, Bojan
Izvornik
Journal of thrombosis and thrombolysis (0929-5305) 39
(2014), 4;
522-531
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
aspirin resistence; multiplate electrode aggregometry; platelet aggregation inhibitors; coronary artery bypass surgery; platelet function
Sažetak
Individual variability in the response to aspirin, has been established by various platelet function assays, however, the clinical relevance of aspirin resistance (AR) in patients undergoing coronary artery bypass grafting (CABG) has to be evaluated. Our working group conducted a randomized controlled trial (NCT01159639) with the aim to assess impact of dual antiplatelet therapy (APT) on outcomes among patients with AR following CABG. Patients that were aspirin resistant on fourth postoperative day (POD 4) were randomly assigned to receive either dual APT with clopidogrel (75 mg) plus aspirin (300 mg)—intervention arm or monotherapy with aspirin (300 mg)—control arm. This exploratory analysis compares clinical outcomes between aspirin resistant patients allocated to control arm and patients that have had adequate platelet inhibitory response to aspirin at POD 4. Both groups were treated with 300 mg of aspirin per day following surgery. We sought to evaluate the impact of early postoperative AR on outcomes among patients following CABG. Exploratory analysis included a total number of 325 patients. Of those, 215 patients with adequate response to aspirin and 110 patients with AR allocated to aspirin monotherapy following randomization protocol. The primary efficacy end point (MACCEs—major adverse cardiac and cardiovascular events) occurred in 10 and 6 % of patients with AR and with adequate aspirin response, respectively (p = 0.27). Non-significant differences were observed in bleeding events occurrence. Subgroup analysis of the primary end point revealed that aspirin resistant patients with BMI > 30 kg/m2 tend to have a higher occurrence of MACCEs 18 versus 5 % (relative risk 0.44 [95 % CI 0.16–1.16] ; p = 0.05). This exploratory analysis did not reveal significant impact of aspirin resistance on outcomes among patients undergoing CABG. Further, sufficiently powered studies are needed in order to evaluate clinical relevance of AR in patients undergoing CABG.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081875-1993 - Otpornost na antitrombocitne lijekove u ishemijskoj bolesti srca i mozga (Miličić, Davor, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Rijeka,
Medicinski fakultet, Zagreb,
Klinička bolnica "Sveti Duh",
Klinički bolnički centar Zagreb,
Medicinski fakultet, Osijek
Profili:
Mate Petričević
(autor)
Davor Miličić
(autor)
Bojan Biočina
(autor)
Marko Boban
(autor)
Tomislav Kopjar
(autor)
Hrvoje Gašparović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE